PMDA — authorised 21 August 2020
- Marketing authorisation holder: Novartis Pharma K.K., Sandoz K.K.
- Status: approved
🇯🇵 Sandostatin in Japan
PMDA authorised Sandostatin on 21 August 2020
Marketing authorisation
Sandostatin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Japan
Frequently asked questions
Is Sandostatin approved in Japan?
Yes. PMDA authorised it on 21 August 2020.
Who is the marketing authorisation holder for Sandostatin in Japan?
Novartis Pharma K.K., Sandoz K.K. holds the Japanese marketing authorisation.